Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Nexalin Technology to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.
Volatility & Risk
Nexalin Technology has a beta of 5.13, suggesting that its share price is 413% more volatile than the S&P 500. Comparatively, Nexalin Technology’s competitors have a beta of 12.49, suggesting that their average share price is 1,149% more volatile than the S&P 500.
Insider & Institutional Ownership
0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 27.7% of Nexalin Technology shares are held by insiders. Comparatively, 14.9% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 0 | 0 | 0 | 0 | N/A |
| Nexalin Technology Competitors | 250 | 768 | 2034 | 101 | 2.63 |
As a group, “Electromedical equipment” companies have a potential upside of 25.25%. Given Nexalin Technology’s competitors higher possible upside, analysts clearly believe Nexalin Technology has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Nexalin Technology and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nexalin Technology | $110,000.00 | -$4.65 million | -2.53 |
| Nexalin Technology Competitors | $986.67 million | $82.19 million | -7.98 |
Nexalin Technology’s competitors have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Nexalin Technology and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -3,088.12% | -154.84% | -122.94% |
| Nexalin Technology Competitors | -152.14% | -47.47% | -5.34% |
Summary
Nexalin Technology competitors beat Nexalin Technology on 8 of the 10 factors compared.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
